pharma · Metastatic castration-resistant prostate cancer. · short-term treatment of insomnia
Orion Laboratories Pty
Orion Laboratories Pty.
Orion Laboratories Pty clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Baton Rouge, USA
- Founded
- 2008
- Employees
- 52
- Programs
- 9
- Drugs
- 20
- Patents
- 0
Orion Laboratories Pty projects
6 ClinicalTrials.gov programs sponsored by Orion Laboratories Pty.
Orion Laboratories Pty has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
3124001
Orion Laboratories Pty.
Metastatic castration-resistant prostate cancer.
1 trial -
3133003
Orion Laboratories Pty.
Chronic Pain due to Ostheoarthritis of the knee
1 trial -
3133004
Orion Laboratories Pty.
CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY
1 trial -
3134003
Orion Laboratories Pty.
Neoplasms benign malignant and unspecified (incl. cysts and polyps)
1 trial -
Arazasetron besylate
Orion Laboratories Pty.
Cisplatine induced hearing loss
1 trial -
SENS-401 (R-Azasetron Besylate)
Orion Laboratories Pty.
Hearing Loss
1 trial
Frequently asked questions
How many clinical projects does Orion Laboratories Pty have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.